CHICAGO—The outgoing president of ASCO, Dr Michael Link from Stanford University School of Medicine in California, answers questions from Peter Goodwin about the progress achieved in cancer clinical science during his year in office. He talks specifically about new research …
AJO
Volker Diehl
George Canellos
Hodgkin’s Disease: 10-Year Results Show Further Benefit From Escalated BEACOPP Therapy
REFERENCE: Abstract 8015, ASCO Annual Meeting Chicago June 1-5, 2007
VOLKER DIEHL, University of Cologne
GEORGE CANELLOS, Dana-Farber Cancer Institute, Boston
Long-term results presented at
VOLKER DIEHL, University of Cologne
GEORGE CANELLOS, Dana-Farber Cancer Institute, Boston
Long-term results presented at
…
Christian Manegold
Roy Herbst
More Support for Bevacizumab in Advanced Lung Cancer
REFERENCE: Abstract LBA7514, ASCO Annual Meeting Chicago June 1-5, 2007
CHRISTIAN MANEGOLD, Heidelberg University, Mannheim
COMMENT: ROY HERBST, MD Anderson Cancer Center, Houston
The benefit of adding bevacizumab
CHRISTIAN MANEGOLD, Heidelberg University, Mannheim
COMMENT: ROY HERBST, MD Anderson Cancer Center, Houston
The benefit of adding bevacizumab
…
Christiane Kuhl
Julie Gralow
MRI Better Than Mammography for Detecting High-Grade Ductal Carcinoma In Situ?
REFERENCE: 1504, ASCO Annual Meeting Chicago June 1-5, 2007
CHRISTIANE KUHL, University of Bonn, Germany
COMMENT: JULIE GRALOW, University of Washington, Seattle
The ASCO meeting
CHRISTIANE KUHL, University of Bonn, Germany
COMMENT: JULIE GRALOW, University of Washington, Seattle
The ASCO meeting
…
IAN SMITH, Royal Marsden Hospital, London
REFERENCE: Lancet 369:29
Confirmation of the life-extending benefits of trastuzumab adjuvant therapy for early breast cancer has been published recently in the Lancet. Ian Smith gave Peter Goodwin three-year follow up results from
Confirmation of the life-extending benefits of trastuzumab adjuvant therapy for early breast cancer has been published recently in the Lancet. Ian Smith gave Peter Goodwin three-year follow up results from
…
 Dennis Slamon |
 George Peoples |
 James Holland |
 Massimo Christofanilli |
Trastuzumab: Mature Results in Early Breast Cancer Show Superiority
REFERENCE: San Antonio Breast Cancer Symposium 2006, Abstract: 52
DENNIS SLAMON, University of California, Los Angeles
Adjuvant therapy regimens containing trastuzumab have proved
…
 Martin Müller |
 Charles Linker |
 Andreas Hochhaus |
 Christian Buske |
 Katarina Le Blanc |
 Stephen Emerson |
 Alessandro Vannucchi |
 Kanti Rai |
 Richard Schlenk |
BCR-ABL Mutations After Imatinib Failure: Impact on Response to Dasatinib
REFERENCE: American Society of Hematology 2006 Orlando: Abstract: 748
MARTIN MÜLLER,
…
 Clifford Hudis |
 Mark Einstein |
 Tony Greco |
 James Berenson |
 Edward Ambinder |
Breast Cancer: HER2 Still a Useful Target After Trastuzumab Resistance
REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 November 2006
CLIFFORD HUDIS, Memorial Sloan-Kettering Cancer Center, New York
COMMENT: EDWARD AMBINDER, Mount
…
 Gordon McVie |
 Martine Piccart |
 Bella Kaufman |
 Jean-Yves Douillard |
ESMO Congress Reviewed
GORDON MCVIE, European Institute of Oncology, Milan
In Istanbul, Gordon McVie gave his opinion about the achievements of the 2006 European Society for Medical Oncology Congress. He added his
…
 George Canellos |
 Sandra Strauss |
 Nancy Baxter |
KIT Mutations in Acute Myeloid Leukemia Confer Higher Relapse Risk
Liver Metastasis Resection Not Curative for Colorectal Cancer
Patients With Node Negative Breast Cancer: Low Risk After Mastectomy
REFERENCES: J Clin Oncol 34:3904, 3927,
…
 Robert Ozols |
 William See |
 Ruth Lupu |
Improving on Standard Treatment in Ovarian Cancer: Have We Hit a Wall?
REFERENCE: Abstract 5002, 2006 ASCO Annual Meeting; N Engl J Med 2006, 354:34-43
ROBERT OZOLS, Fox Chase Cancer Center, Philadelphia
The combination
…
 Mark Socinski |
 Bruce Johnson |
 Neil Shah |
 Doug Smith |
Sunitinib Multi-Targeted Oral Anti-Angiogenic Therapy Responses in Lung Cancer
REFERENCE: Abstract 7001
Mark A. Socinski, Univerisity of North Carolina, Chapel Hill
The use of anti-angiogenic therapy for treating patients with non-small cell
…